Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.
Malaria imposes an enormous health burden on people living in the tropics and effective control measures are urgently needed. The vast majority of deaths in humans from malaria are caused by one species of the protozoan, Plasmodium falciparum. An efficacious and cost-effective vaccine against this parasite is considered a holy grail of modern molecular medicine. A vaccine that targets liver-stage parasites would prevent infection from reaching the blood and causing clinical disease. Among around 40 known Plasmodium falciparum antigens, only a few are expressed exclusively by mosquito-transmitted sporozoites or infected hepatocytes. Studies in humans have consistently related immune responses to these antigens with resistance to infection or disease, providing a powerful rationale for the development of pre-erythrocytic vaccines. By dissecting the mechanism(s) of immunity to these antigens, we can best evaluate in different delivery systems epitopes associated with protection as components of a focused and coordinated multiantigen malaria vaccine strategy.
Taylor-Robinson
Andrew W
AW
School of Biology, University of Leeds, UK. bgyawtr@leeds.ac.uk
D000818:Animals; D000953:Antigens, Protozoan / Q000096:biosynthesis / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004912:Erythrocytes / Q000469:parasitology*; D006790:Host-Parasite Interactions / Q000276:immunology / Q000502:physiology*; D006801:Humans; D008099:Liver / Q000469:parasitology; D008288:Malaria / Q000097:blood* / Q000276:immunology* / Q000469:parasitology; D017780:Malaria Vaccines / Q000276:immunology*; D010961:Plasmodium / Q000254:growth & development / Q000276:immunology / Q000502:physiology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D001613:beta 2-Microglobulin / Q000276:immunology
D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D001613:beta 2-Microglobulin